세계의 항구토제 시장

Global Antiemetic Drugs Market to Reach US$8.8 Billion by 2030

The global market for Antiemetic Drugs estimated at US$6.1 Billion in the year 2023, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2023-2030. Chemotherapy Application, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$3.2 Billion by the end of the analysis period. Growth in the Gastroenteritis Application segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 5.0% CAGR

The Antiemetic Drugs market in the U.S. is estimated at US$1.7 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 5.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.3% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Antiemetic Drugs Market - Key Trends and Drivers Summarized

Why Are Antiemetic Drugs Essential in Modern Medicine?

Antiemetic drugs are essential in modern medicine due to their critical role in preventing and treating nausea and vomiting, symptoms that can significantly impact a patient’s quality of life. These symptoms are commonly associated with a variety of conditions and treatments, including chemotherapy, surgery, pregnancy (morning sickness), and motion sickness. By blocking specific receptors in the body that trigger vomiting, antiemetics provide relief and enable patients to maintain their normal daily activities. This is particularly important in cancer treatment, where the management of chemotherapy-induced nausea and vomiting (CINV) can improve patient adherence to treatment regimens, thereby enhancing therapeutic outcomes. The broad application of antiemetic drugs across multiple medical fields underscores their importance in patient care and symptom management.

What Are the Key Classes of Antiemetic Drugs and Their Mechanisms?

The key classes of antiemetic drugs include serotonin (5-HT3) receptor antagonists, dopamine antagonists, neurokinin-1 (NK1) receptor antagonists, antihistamines, and anticholinergics. Each class targets different pathways involved in the emetic response. Serotonin receptor antagonists, such as ondansetron, block the action of serotonin, a key neurotransmitter in the vomiting reflex, and are particularly effective in managing CINV. Dopamine antagonists, like metoclopramide, inhibit dopamine receptors in the brain that trigger nausea and vomiting. NK1 receptor antagonists, such as aprepitant, prevent substance P from binding to NK1 receptors, offering prolonged antiemetic protection. Antihistamines and anticholinergics, including drugs like diphenhydramine and scopolamine, are effective in treating motion sickness and vestibular disorders by blocking histamine and acetylcholine receptors, respectively. The diversity of these mechanisms allows for targeted therapy based on the underlying cause of nausea and vomiting.

How Are Technological Advancements and Research Influencing Antiemetic Drug Development?

Technological advancements and ongoing research are significantly influencing the development of new antiemetic drugs. Innovations in drug delivery systems, such as transdermal patches and orally disintegrating tablets, enhance the convenience and efficacy of antiemetic treatments. Additionally, advances in pharmacogenomics are enabling personalized medicine approaches, allowing clinicians to tailor antiemetic therapy based on individual genetic profiles and predicted responses to treatment. Research into the mechanisms of nausea and vomiting continues to identify new therapeutic targets, leading to the development of novel antiemetics with improved efficacy and safety profiles. Clinical trials and real-world studies are also providing valuable data on the effectiveness of combination therapies, where multiple antiemetic drugs are used together to achieve better control of symptoms.

What Factors Are Driving Growth in the Antiemetic Drugs Market?

The growth in the antiemetic drugs market is driven by several factors related to technological advancements, increasing incidence of nausea-inducing conditions, and evolving healthcare practices. The rising prevalence of cancer and the corresponding increase in chemotherapy treatments are major drivers, as effective management of CINV is crucial for patient compliance and quality of life. Technological innovations in drug formulations and delivery methods enhance patient convenience and adherence to antiemetic therapies. Additionally, the growing number of surgical procedures and the widespread occurrence of postoperative nausea and vomiting (PONV) drive demand for these drugs. The increasing recognition of the importance of quality of life in chronic disease management and supportive care also boosts the market. Furthermore, expanding research into the underlying mechanisms of nausea and vomiting is leading to the development of more targeted and effective treatments. The integration of antiemetic drugs into comprehensive care plans for conditions such as pregnancy and vestibular disorders further propels market growth. Collectively, these factors contribute to a robust and dynamic market landscape for antiemetic drugs.

Select Competitors (Total 12 Featured) -

• Abbott Laboratories, Inc.
• Astellas Pharma, Inc.
• Baxter International, Inc.
• Cipla Ltd.
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi-aventis U.S. LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Antiemetic Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Cancer and Chemotherapy Throws the Spotlight on Antiemetic Drugs
  • Rising Cases of Motion Sickness and Vestibular Disorders Spur Growth in Antiemetic Drug Market
  • Increasing Prevalence of Postoperative Nausea and Vomiting (PONV) Expands Addressable Market Opportunity
  • Development of Personalized Medicine Strengthens Business Case for Tailored Antiemetic Therapies
  • Innovations in Pharmacogenomics Generate New Market Opportunities
  • Growing Awareness of Quality of Life Issues Drives Adoption of Antiemetic Drugs
  • Integration of Antiemetic Drugs in Chronic Disease Management Plans Generates Demand
  • Increasing Use of Combination Therapies Drives Adoption of Multifaceted Antiemetic Approaches
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Antiemetic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Antiemetic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Antiemetic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Gastroenteritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Gastroenteritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Gastroenteritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 13: World Antiemetic Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for General Anesthetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for General Anesthetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for General Anesthetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pregnancy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Pregnancy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Pregnancy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Motion Sickness by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Motion Sickness by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Motion Sickness by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Antiemetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Canada Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Canada 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030
• JAPAN
  • Antiemetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 29: Japan Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Japan Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Japan 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030
• CHINA
  • Antiemetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 32: China Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: China Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: China 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030
• EUROPE
  • Antiemetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 35: Europe Recent Past, Current & Future Analysis for Antiemetic Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 36: Europe Historic Review for Antiemetic Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Europe 16-Year Perspective for Antiemetic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 38: Europe Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Europe Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Europe 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030
• FRANCE
  • Antiemetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 41: France Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: France Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: France 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030
• GERMANY
  • Antiemetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 44: Germany Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Germany Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Germany 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 47: Italy Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Italy Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Italy 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Antiemetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 50: UK Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: UK Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: UK 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Rest of Europe Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Rest of Europe 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Antiemetic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Asia-Pacific Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Asia-Pacific 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 59: Rest of World Recent Past, Current & Future Analysis for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Rest of World Historic Review for Antiemetic Drugs by Application - Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: Rest of World 16-Year Perspective for Antiemetic Drugs by Application - Percentage Breakdown of Value Sales for Chemotherapy, Gastroenteritis, General Anesthetics, Pregnancy, Motion Sickness and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION